首页> 美国卫生研究院文献>Case Reports in Oncological Medicine >A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases
【2h】

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases

机译:肝动脉灌注L-叶酸调节5-氟尿嘧啶联合静脉注射伊立替康和西妥昔单抗联合肝切除术后原发性无法切除的大肠肝转移患者的长期生存病例报告。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 43-year-old women admitted to our hospital for weight loss, anorexia, and abdominal pain was diagnosed with sigmoid neoplasm and multiple bilobar liver metastases. This patient received six cycles of systemic FOLFOX prior to a laparoscopically assisted anterior resection of the rectosigmoid for a poorly differentiated invasive adenocarcinoma T2N2M1, K-RAS negative (wild type). Hepatic arterial infusion (HAI) of L-folinic acid modulated 5-fluorouracil (LV/5-FU) with intravenous (iv) irinotecan (FOLFIRI) and cetuximab as adjuvant therapy resulted in a complete metabolic response (CR) with CEA normalization. A right hepatectomy extended to segment IV was performed resulting in (FDG-)PET negative remission for 7 months. Solitary intrahepatic recurrence was effectively managed by local radiofrequent ablation following 6c FOLFIRI plus cetuximab iv. Multiple lung lesions and recurrence of pulmonary and local lymph node metastases were successfully treated with fractionated stereotactic radiotherapy (50 Gy) and iv LV/5-FU/oxaliplatin (FOLFOX) plus cetuximab finally switched to panitumumab with CR as a result. At present the patient is in persistent complete remission of her stage IV colorectal cancer, more than 5 years after initial diagnosis of the advanced disease. Multidisciplinary treatment with HAI of chemotherapy (LV/5-FU + CPT-11) plus EGFR-inhibitor can achieve CR of complex unresectable LM and can even result in hepatectomy with possible long-term survival.
机译:一名因体重减轻,厌食和腹痛而入院的43岁妇女被诊断出患有乙状结肠肿瘤和多发性肝叶肝转移。该患者接受了六个周期的全身性FOLFOX治疗,之后因腹腔镜辅助行直肠乙状结肠切除术治疗了低分化浸润性腺癌T2N2M1,K-RAS阴性(野生型)。肝动脉输注L-亚叶酸调节的5-氟尿嘧啶(LV / 5-FU)与静脉内(iv)伊立替康(FOLFIRI)和西妥昔单抗作为辅助治疗可导致CEA正常化的完全代谢反应(CR)。右肝切除术扩展到IV段,导致(FDG-)PET阴性缓解7个月。 6c FOLFIRI加西妥昔单抗iv后局部局部射频消融有效治疗了孤立性肝内复发。采用分级立体定向放疗(50 Gy)和iv LV / 5-FU /奥沙利铂(FOLFOX)加西妥昔单抗加静脉西妥昔单抗治疗后,成功地将多发性肺部病变以及肺和局部淋巴结转移的复发成功治疗为CR。目前,患者在初步诊断为晚期疾病后超过5年,一直持续完全缓解其IV期大肠癌。化疗HAI(LV / 5-FU + CPT-11)加EGFR抑制剂的多学科治疗可以实现复杂的不可切除LM的CR,甚至可能导致肝切除并可能长期存活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号